Michael Imeh

Fellow,🩸& 🦀 Memorial Cancer Institute| IM alum @NYCHHC/Lincoln| alum @CMULNigeria| medical education| 🦀 prevention| creative writing| Blaugrana. Views = mine

[Veli Bakalov, MD @HemeOncBuddy]

Heme/onc fellows starting July — save this.

A free, oncologist-built study + reference platform:
• Trials database
• Board prep notes
• Heme/onc flashcards
• Staging flashcards

20 randomly selected entries verified against OpenEvidence
@EvidenceOpen = no errors

🔗 https://t.co/C3S0IkiCJQ

[Michael Imeh @imeh_md]

@IAmOluwanimilo Lol yeah.

[Michael Imeh @imeh_md]

@IAmOluwanimilo Really? Why? PSV were Dutch champions last year and are currently top of their league. The loss to the Dutch champions isn't the problem. Because PSV can hold their own against anyone. The problem is the way and manner the loss happened. Such a poor team performance at the back.

[The Lancet Haematology @TheLancetHaem]

“I would teach a medical student something and it seemed to trigger a lightbulb in their head, and I thought, I wish someone else had told me about that, so I just started sharing more widely.”

Profile: @AaronGoodman33 aka Papa Heme
@csoncol @UCSanDiego
https://t.co/NO8et7XRHB

[Vincent Rajkumar @VincentRK]

Just out in the Journal of Clinical Oncology! @JCO_ASCO

A paradigm changing paper on MGUS and Smoldering Myeloma @FrancescoMaura4

And it’s Open Access!!
https://t.co/svHThmjiCm

KEY FINDINGS:

1) We identify for the first time myeloma defining genomic events to differentiate biologic premalignancy (genomic MGUS) from biologic malignancy (genomic Myeloma).

2) We find that most of smoldering myeloma and almost all of high risk smoldering myeloma is biologic malignancy with genomic features indistinguishable from active myeloma

3) We show that some myeloma defining genomic events are also associated with high risk of progression resulting in a genomic model of risk stratification of Smoldering Myeloma.

4) We show that combining the genomic model (genomics) with the IMWG2020 model (clone size) provides a better risk stratification than either alone.

5) We provide the code and information where if you have access to sequencing you can run this yourself to determine whether the patient has genomic MGUS or genomic Myeloma

This is a major collaborative international effort with top centers and researchers pooling data so we can finally address these important questions. @FrancescoMaura4 @szusmani @Leif_Bergsagel @myelomaMD @DrOlaLandgren @DrKrinaPatel @Myeloma_Doc @Rfonsi1 @DrGarethMorgan1 @MSKCancerCenter
@MayoClinic @SylvesterCancer @Perlmutter_CC and more.

[Lincoln Medical Center IM Residency Program @lincolndepmed]

Happy to see our future Heme/Onc and Alumni presenting at #ASCO25✨🩸So proud of them!

[Michael Imeh @imeh_md]

@stve_nwo Thanks!

[Michael Imeh @imeh_md]

Excited for the start of a new chapter.
Grateful for mentorship and support all the way! 🎉🎉#HemeOnc

[Michael Imeh @imeh_md]

@bukinoah Thank you!

[Michael Imeh @imeh_md]

@Richy__Green Thank you man ❤️

[Michael Imeh @imeh_md]

@oyster_doctor Thank you!

[Michael Imeh @imeh_md]

@Victoruzor_ Thank you

[Michael Imeh @imeh_md]

@__eante Thank you my guy!

[Michael Imeh @imeh_md]

@Bibi_Ajayi_ Thank you!

[Michael Imeh @imeh_md]

@the_olusesan14 😏

[Michael Imeh @imeh_md]

@anyholla Thank you!

[Michael Imeh @imeh_md]

@Obiwetaaku Thank you! 😁

[Michael Imeh @imeh_md]

@ancientmind Haha. Thank you my chief 🙌

[Michael Imeh @imeh_md]

@adewalemayowa_ @Adanzy17 Thanks man! 😁

[Michael Imeh @imeh_md]

@Adanzy17 ❤️

[Michael Imeh @imeh_md]

@Makuo_Ozoude Thanks a lot!